# "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM

> **NCT00402012** · PHASE4 · COMPLETED · sponsor: **Pennington Biomedical Research Center** · enrollment: 24 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT00402012
- **Lead sponsor:** Pennington Biomedical Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00402012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00402012, ""TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00402012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*